Antibiotic resistance ranks among the gravest threats to modern medicine. As bacteria mutate and adapt, once-effective drugs become powerless. The fallout extends beyond treating infections: it complicates surgery, cancer treatment, and routine medical care.
Rather than chase entirely new antibiotics, researchers are pursuing a smarter approach. Antibiotic adjuvants work as molecular companions, restoring potency to existing drugs without directly attacking bacteria themselves.
A team at Cold Spring Harbor Laboratory has now demonstrated this strategy in action. Researchers led by Professor John Moses, working with collaborators at Scripps Research, have revived vancomycin's ability to kill drug-resistant bacteria.
Vancomycin has long been a weapon against severe infections, including those caused by MRSA and Clostridium difficile. Yet these pathogens have developed ways to survive the drug, spreading through hospitals and communities as untreatable superbugs.
The breakthrough hinges on blocking a bacterial enzyme called secreted antigen A. A molecule named pghi-4, discovered in Moses' lab in 2020, does exactly that. When researchers treated drug-resistant E. faecium with vancomycin plus pghi-4, the antibiotic regained its killing power.
Building the adjuvant required years of chemistry work. Moses' team developed a technique called diversity oriented clicking, or DOC, that accelerates molecule discovery. The method has produced a library of more than 150 compounds already contributing to research on resistance and cancer.
What strikes Moses most is how the discovery emerged organically from fundamental research, not from hunting for a solution. "Reaction development led to the discovery of the first inhibitor of an important enzyme involved in antibiotic resistance," he said. The team continues refining the process to keep the library current and accessible to other researchers.
The findings suggest a path forward as resistance spreads globally. Rather than waiting for new drugs, scientists can chemically engineer molecules that restore old ones. The approach may eventually help combat resistant tuberculosis and other drug-proof infections.
Making the molecular library available to the broader research community multiplies the potential impact. Other teams can now test similar strategies against additional pathogens, using the same chemical framework Moses and his colleagues developed.
Author Jessica Williams: "This is elegant problem-solving disguised as chemistry, and it could buy medicine precious time as resistance continues outpacing new drug development."
Comments